Shalby Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 15 Jul 2026 | Healthcare Services | Market Cap: ₹1.7K Cr
Hospital business expects 60% to 70% more work growth in existing hospitals over the next 2 years due to infrastructure upgrades including robotics and diagnostics. Hospital business aims to stabilize and grow EBITDA margins to 20% per unit, potentially reaching 23%-25% at 50% higher occupancy in coming quarters.
From Shalby Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹153
Market Cap
₹1.7K Cr
P/E Ratio
42.0
How does Shalby Ltd rank in Healthcare Services?
Compare Shalby Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Shalby Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹287 Cr, net profit ₹18 Cr.
Full financials →📊 Revenue & Sales Performance
- →Hospital business expects 60% to 70% more work growth in existing hospitals over the next 2 years due to infrastructure upgrades including robotics and diagnostics.
- →Additional bed capacity available for ramp-up, e.g., 50+ beds in Delhi NCR region planned to be utilized at the right time.
- →ARPOB (Average Revenue Per Occupied Bed) expected to grow around 5%-6% historically; robotics and rate revisions by government/insurance to contribute to higher ARPOB.
- →Implant business showing strong revenue growth: 65% growth last year and similar in FY '26, with a large $35 billion global market opportunity and geographic expansion underway.
- →New product launches and regulatory approvals in multiple countries (Malaysia, Argentina, South Korea, Vietnam, Iran, etc.) expected to drive international sales growth over next 12-14 months.
- →Overall revenue growth expected to be supported by ramp-up in occupancy, outpatient/inpatient counts, implant sales, and higher realizations from new technology adoption.
📈 Profitability & Margins
- →Hospital business aims to stabilize and grow EBITDA margins to 20% per unit, potentially reaching 23%-25% at 50% higher occupancy in coming quarters.
- →Expansion plans include ramping up existing hospital capacity by 60%-70% with investments in infrastructure, robotics, diagnostics, and clinical talent.
- →No significant capex expected in hospital or implant business over next 12 months; focus on operational ramp-up.
- →MedTech/implant business is transitioning from turnaround to structured growth with revenue more than doubling YoY and improving margins.
- →Implant business capacity issues largely resolved; regulatory challenges persist but targeted market expansions underway.
- →EBITDA breakeven achieved in MedTech; PAT breakeven expected in future but no specific guidance.
- →ARPOB expected to grow 5%-6% driven by rate revisions and robotics.
- →Net debt expected to reduce over next 12 months due to stronger EBITDA and lower capex needs.
🏗️ Capital Expenditure Plans
- →No significant capex is planned over the next 12 months for the hospital or implant business.
- →Recent heavy investments made in infrastructure upgrades, high-end robotics, and diagnostics (including installation of new PET CT scan).
- →Planned addition of 2 more radiation oncology bunkers in Mohali and Delhi NCR within the next 12 to 18 months.
- →Bed addition of about 50 beds planned in Delhi NCR at an appropriate time.
- →Capex related to implant business (instruments and other equipment) largely incurred; minimal similar capex expected over next 2-3 years.
- →Future investments in technology and strategic upgrades, especially robotics, to continue on a strategic basis.
- →No aggressive capex plans on franchisee expansion; franchisee growth not prioritized currently.
💰 Fundraising & Capital Structure
- →No significant capex is planned over the next 12 months for either the hospital or implant business, suggesting limited need for large fundraising.
- →The implant business's funding requirement is expected to be 30% to 40% of the EBITDA it generates going forward.
- →Management expects net debt to be slightly lower 12 months from now due to increased profitability and ramp-up in implant sales.
- →There is optimism about debt reduction as hospital business EBITDA grows and implant business funding needs reduce.
- →No specific plans for raising new debt or equity were mentioned in the call.
📋 Order Book & Pipeline
Key Metrics
Continue your research
What Shalby's management said in earlier quarters
Others in Healthcare Services this season
- Vijaya Diagnostic Centre Ltd (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnost.'s Q3 FY26 earnings call — and…
- Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Chandan Healthca (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Childrens Medicare Ltd (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
Frequently Asked Questions
What were Shalby Ltd Q3 FY26 results?
Hospital business expects 60% to 70% more work growth in existing hospitals over the next 2 years due to infrastructure upgrades including robotics and diagnostics. Hospital business aims to stabilize and grow EBITDA margins to 20% per unit, potentially reaching 23%-25% at 50% higher occupancy in coming quarters.
What is Shalby Ltd share price analysis?
Shalby Ltd currently shows a neutral. The stock trades at a P/E of 42.0 with a market cap of ₹1,652 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shalby Ltd planning capital expenditure?
No significant capex is planned over the next 12 months for the hospital or implant business.
Keep Shalby Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.